Treatment Of Chemotherapy Articles & Analysis
33 news found
Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamous non-small cell lung cancer and mesothelioma Eagle Pharmaceuticals, Inc. ...
The end goals are to determine whether this targeted method of delivering chemotherapy can extend survival while also improving quality of life. Although pancreatic cancer treatment has improved, pancreatic cancer patients continue to have poor outcomes – partially due to the tissue surrounding the tumor hampering intravenously delivered ...
ByxCures
(“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, orally administered progesterone receptor (PR) antagonist, ...
BNCT has the potential to deliver highly effective, cell-localized radiation therapy to treat tumors with minimal impact on the patient's quality of life compared to other available treatment options, such as radiation, chemotherapy or biological treatment modalities. ...
The study involves patients with recently diagnosed metastatic pancreatic adenocarcinoma who are scheduled to receive chemotherapy treatment with gemcitabine and abraxane. Vault Health’s decentralized research capabilities will allow Faeth to extend the NEAAR clinical trial beyond physical clinical trial sites to patients living across the country. ...
ByxCures
“We believe that our novel off-the-shelf personalized immunotherapy may offer a safe and effective targeted personalized treatment option for advanced prostate cancer patients who failed the current standard of care,” Dr. ...
(Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for VBI-1901, a bivalent gB/pp65 immunotherapeutic vaccine candidate for the treatment of glioblastoma (GBM). In June 2021, the FDA ...
“We continue to be motivated by the data seen in this Phase 2a study of VBI-1901 as we endeavor to provide new treatment options to patients with very few available to them,” said David E. ...
” The Cellworks Biosimulation Platform simulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and identifies novel drug combinations for treatment-refractory patients. ...
BNCT has the potential to deliver highly effective and cell-localized radiation therapy to treat tumors with minimal impact on the patient’s quality of life compared to other radiation, chemotherapy or biological treatment modalities currently in use. Neutron Therapeutics Inc. and the Helsinki University Hospital are collaborating to launch the first ...
In the past decade, pharmaceutical companies have been reluctant to re-address pain treatments following the opioids crisis. However, we see a change on the horizon. ...
“Many of these patients have survived surgery, chemotherapy, radiation and other treatments, only to face a long-term, painful battle with lymphedema. ...
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces the exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug development program, including lead and back-up compounds, preclinical data and a patent estate, from ...
Under this agreement, GI Innovation and AstraZeneca will conduct a clinical trial assessing triplet combination regimen of GI-101, Imfinzi® (durvalumab) and chemotherapy for the treatment of small cell lung cancer, gastric/gastroesophageal junction cancer, biliary tract cancer and triple-negative breast cancer in USA, Australia and South Korea. ...
As we advance our clinical program supporting glucarpidase globally, we are excited to see rigorous consensus results that advance our understanding of the efficacy and value of glucarpidase in appropriate patients.” High dose MTX chemotherapy is used to treat or prevent the recurrence of certain types of cancer in both adults and children, such as leukaemia, lymphoma, and ...
In animal models of GBM, Lixte’s novel protein phosphatase inhibitor, LB-100, enhances the effectiveness of radiation, temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment in the clinic. ...
Unfortunately, many medications, such as anticancer, antibiotics, and antifungal treatments, have severe toxicities when overdosed and are ineffective when underdosed. ...
“This patient’s cancer was not responding to conventional chemotherapy treatments, and I was running out of options. Therefore, we were hopeful the test would have the potential to find an effective therapy,” said Dr. ...
Improved quality of care and significant cost savings using the test to guide adjuvant chemotherapy treatment Analysis based on first results from the independent RxPONDER study which identified the majority of women with one to three positive nodes who receive no benefit from chemotherapy Exact Sciences today announced results from a ...
Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Merck’s supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC), in combination with chemotherapy as neoadjuvant ...